Table 2.

IC₅₀ of tested compounds 4a–e, 7a–e, and Erlotinib.

Comp.	Cell Viability %	Antiproliferative Activity IC50 ± SEM (nM)
		A-549	MCF-7	Panc-1	HT-29	Average (GI50)
4a	91	31 ± 3	33 ± 3	36 ± 3	36 ± 3	34
4b	89	41 ± 4	43 ± 4	46 ± 4	48 ± 4	45
4c	87	78 ± 8	79 ± 8	83 ± 8	81 ± 8	80
4d	86	90 ± 9	95 ± 9	98 ± 9	97 ± 9	95
4e	90	123 ± 12	127 ± 12	135 ± 13	137 ± 13	130
7a	89	57 ± 6	59 ± 6	62 ± 6	65 ± 6	61
7b	93	63 ± 6	65 ± 6	67 ± 6	67 ± 6	65
7c	91	70 ± 7	74 ± 7	75 ± 7	76 ± 7	74
7d	89	50 ± 5	53 ± 5	57 ± 5	57 ± 5	54
7e	85	126 ± 13	130 ± 13	136 ± 13	143 ± 14	134
Erlotinib	-	30 ± 3	40 ± 3	30 ± 3	30 ± 3	33